As the Healthcare Reform in China spreads nationwide to cut prices of drugs and improve their efficacy and safety, flourishing Chinese biotechnology companies are increasingly investing in new advances in gene and cell therapy. Bioventure companies are under mounting pressure to offer more personalized treatment while keeping up with increased regulations and quality standards in the market, driven by increased regulatory requirements globally and locally. In the wake of the growth in biosimilars markets and the shift to translational research, the push for innovation in the industry ushers in industrialization challenges coupled with heightened R&D standards and the requirement for more regulations. Evidently, when it comes to discovery in research, development, and production of biotherapeutics, it is a daunting task to increase speed to market and boost the productivity, all while ensuring the quality, purity, and integrity of the product. With a strong technical team throughout Asia, including service engineers and field application specialists across the APAC region, Sartorius, an international provider of laboratory and process technologies and equipment is changing this narrative. Through a wide range of innovative products and high-quality services, the company helps its customers in the biotech, pharmaceutical, and food industries implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time and cost-efficient manner.

Built with a singular focus on science research, pharmaceutical, and biopharmaceutical manufacturing, Sartorius is well-positioned as a comprehensive solutions provider across the value chain from R&D, production, to in-process Quality Control (QC). “Covering the entire value-added chain of the biopharmaceutical, Sartorius products and services ensure novel therapies reach the market faster and are more accessible to more people worldwide,” mentions Grace Johnston, Head of Marketing at Sartorius.

Sartorius Bioprocess Division provides innovative single-use products and equipment for the manufacture of biologics, enabling more efficient and less expensive production. Through the Bioprocess Solutions Division, Sartorius offers a broad product portfolio that covers all steps in the production of a biopharmaceutical. The company’s core technologies, such as filtration, fermentation, cell cultivation, and single-use bags and containers have been leading market positions for years. Sartorius’ Laboratory Products and Services Division, on the other hand, equips laboratories performing research and quality control with premium lab essentials—market-leading laboratory products, consumables, and services—to simplify workflows and advance speed to market.

Sartorius’ revolutionary technologies including the iQue Screener PLUS provide rapid, multifactorial results to enable deeper insights and ensure the choice, quality, and integrity of the client’s biopharmaceutical product. Sartorius’ revolutionary technologies including the iQue Screener PLUS provide rapid, multifactorial results to enable deeper insights and ensure the choice, quality, and integrity of the client’s biopharmaceutical product.